ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "spondyloarthritis"

  • Abstract Number: 1029 • ACR Convergence 2020

    Clinical Characteristics of Patients with Axial Spondyloarthritis in China: Results from the ChinaAS Registry

    Jinmei Su1, Runsheng Wang2, Ping Zhu3, Yanhong Wang4, Shangzhu Zhang1, Linyi Peng1, Min Yang5, Ling Lei6, Li Qin7, Mengtao Li8 and Xiaofeng Zeng8, 1Peking Union Medical College Hospital, Department of Rheumatology, Beijing, China (People's Republic), 2Columbia University Irving Medical Center, Division of Rheumatology, New York, NY, 3Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi, China (People's Republic), 4Department of Epidemiology and Bio-statistics, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, Beijing, China (People's Republic), 5Department of Rheumatology and Immunology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China (People's Republic), 6Department of Rheumatology and Immunology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China (People's Republic), 7Department of Rheumatology, The First People's Hospital of Yunnan Province, Kunming, China (People's Republic), 8Peking Union Medical College Hospital, Department of Rheumatology, Beijing, Beijing, China (People's Republic)

    Background/Purpose: The ChinaAS is a nationwide, multicenter registry of patients with axial spondyloarthritis (SpA) in China to facilitate research in epidemiology, pathogenesis, diagnosis and treatment…
  • Abstract Number: 1330 • ACR Convergence 2020

    Subclinical atherosclertoic disease in ankylosing spondylitis and non-radiographic axial spondyloarthritis. A multicenter study with 806 patients.

    Inigo Gonzalez-Mazon1, Javier Rueda-Gotor2, Ivan Ferraz-Amaro3, Lara Sanchez-Bilbao4, David Martinez-Lopez5, Fernanda Genre6, Natalia Palmou Fontana7, Vanesa Calvo-Río2, Sara Remuzgo-Martínez6, Veronica Pulito-Cueto6, Alfonso Corrales8, Leticia Lera-Gómez6, Virginia Portilla6, Cristina Mata9, Vanesa Hernández-Hernández10, Santos Castañeda11, Esther Francisca Vicente-Rabaneda12, C Fernandez-Carballido13, M Paz Martínez-Vidal14, David Castro-Corredor15, Joaquín Anino-Fernández15, Juan Carlos Quevedo-Abeledo16, Carlos Rodríguez-Lozano17, María Luz García Vivar,18, Eva Galínez-Agirregoikoa18, C. Fernandez-Diaz19, Javier Llorca20, Raquel López-Mejías6, Esther Montes-Perez21, Diana Peiteado22, Chamaida Plasencia23, Alejandro Balsa-Criado24, Nuria Barbarroja25, Lourdes Ladehesa-Pineda26, Rafaela Ortega-Castro27, Eduardo Collantes-Estévez26, Ricardo Blanco28 and Miguel Ángel González-Gay29, 1Hospital Universitario Marques de Valdecilla, Bezana, Spain, 2H.U. Marques de Valdecilla, Santander, Spain, 3Division of Rheumatology. Hospital Universitario de Canarias. Spain., Santa Cruz de Tenerife, Spain, 4Hospital Universitario Marques de Valdecilla, Santander, Spain, 5Hospital Universitario Marques de Valdecilla, Santander (SPAIN), Spain, 6Research group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic bone Diseases of the Musculoskeletal System, IDIVAL, Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, 7UNIVERSITARY HOSPITAL MARQUES VALDECILLA, Santander, Spain, 8Research group on genetic epidemiology and atherosclerosis in systemic diseases and in metabolic bone diseases of the musculoskeletal system, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, 9Hospital de Laredo, Santander, Spain, 10Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain, 11Princesa University Hospital, Universidad Autónoma, Madrid, Madrid, Spain, 12Hospital Universitario de la Princesa, IIS-Princesa, UAM, Madrid, Madrid, Spain, 13H San Juan, Alicante, Spain, 14Hospital General Universitario de Alicante, Alicante, Spain, 15Hospital General Universitario de Ciudad Real, Ciudad Real, Spain, 16Hospital Dr. Negrín, Las Palmas de Gran Canaria, Spain, 17Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain, 18Hospital Universitario Basurto, Bilbao, Spain, 19H. Marqués de Valdecilla, Madrid, Spain, 20School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), Santander, Spain, 21Diagnóstico Médico Cantabria (DMC), Santander, Spain, 22Hospital Universitario La Paz-IdiPaz, Madrid, Spain, 23Rheumatology, La Paz University Hospital-IdiPAZ, madrid, Spain, 24HOSPITAL UNIVERSITARIO LA PAZ, madrid, Spain, 25Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Cordoba, Spain, 26Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Córdoba, Spain, 27Hospital Universitario Reina Sofía, Córdoba, Spain, 28Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, 29Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain

    Background/Purpose: Cardiovascular (CV) mortality and morbidity is increased in ankylosing spondylitits (AS) as compared to the general population. Carotid plaque, considered as a surrogate marker…
  • Abstract Number: 1444 • ACR Convergence 2020

    Cluster-randomized Pragmatic Clinical Trial Evaluating the Potential Benefit of a Tight-control and Treat-to-target Strategy in Axial Spondyloarthritis: The Results of the TICOSPA Trial

    Anna Molto1, Clementina Lopez-Medina2, Filip Van den Bosch3, Annelies Boonen4, Casper Webers4, Emmanuelle Dernis5, Floris van Gaalen6, Martin Soubrier7, Pascal Claudepierre8, Athan Baillet9, Mirian Starsman-Kool10, Anneke Spoorenberg11, Désirée van der Heijde12 and Maxime Dougados13, 1Rheumatology Department, Cochin Hospital, APHP, Paris, France, Paris, France, 2INSERM U1153, Universtity of Paris, PAris, France, 3Ghent University Hospital, Ghent, Belgium, 4Maastricht University Medical Center, Maastricht, Netherlands, 5CH Le Mans, department of rheumatology, Le Mans, France, 6Leiden University Medical Center (LUMC), Leiden, Netherlands, 7CHU Gabriel Montpied, Clermont-Ferrand, France, 8Hôpital Henri Mondor, Université Paris Est Créteil, EA 7379 EpiDermE, department of rheumatology, Créteil, France, 9CHU Grenoble, Echirolles, France, 10ATRIUM Medical Center, Heerlen, 11University Medical Centre Groningen and Medical centre Leeuwarden, Groningen, Netherlands, 12Leiden University Medical Center, Leiden, Netherlands, 13Université de Paris, Department of Rheumatology, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France

    Background/Purpose: Recommendations for axial spondyloarthritis (axSpA) management include tight control and treat-to-target (TC), but no study has evaluated its potential benefit. The objective of this…
  • Abstract Number: 1864 • ACR Convergence 2020

    How to Diagnose Axial Spondyloarthritis in 2020? A Data-Driven Estimation of the Disease Probability in Patients with a priori Different Likelihoods of the Diagnosis

    Denis Poddubnyy1, Fabian Proft2, Joachim Sieper2 and Imke Redeker3, 1Charité – Universitätsmedizin Berlin, Berlin, Germany, 2Charité Universitätsmedizin Berlin, Berlin, Germany, 3German Rheumatism Research Center Berlin, Berlin, Germany

    Background/Purpose: The diagnosis of axial spondyloarthritis (axSpA) is often delayed by several years and reducing that gap between symptom onset and diagnosis poses a major…
  • Abstract Number: 1890 • ACR Convergence 2020

    Daily Management of Patients with Axial Spondyloarthritis: Self-monitoring of Disease Activity with a Smartphone App Is Feasible – a Proof of Concept Study

    Uta Kiltz1, Robin Kempin1, Jutta Richter2, Anna Schlegel1, Xenofon Baraliakos1, Styliani Tsiami3, Ioana Andreica1, Bjoern Buehring4, David Kiefer1 and Juergen Braun1, 1Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany, 2Rheumatology and Hiller Research Unit, Heinrich-Heine-University Duesseldorf, Medical Faculty, Duesseldorf, Germany, Duesseldorf, Germany, 3Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, 4Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Velbert, Germany

    Background/Purpose: Assessment and monitoring of disease activity and functioning is of major importance for the course of axial spondyloarthritis (axSpA). This is equally important for…
  • Abstract Number: 2021 • ACR Convergence 2020

    The Reliability of Scoring Sonographic Entheseal Abnormalities – the Diagnostic Ultrasound Enthesitis Tool (DUET) Study

    Lihi Eder1, Sibel Aydin2 and Gurjit Kaeley3, 1Women’s College Research Institute, University of Toronto, Toronto, ON, Canada, 2University of Ottawa Faculty of Medicine, Rheumatology, Ottawa, ON, CANADA; The Ottawa Hospital Research Institute, Ottawa, ON, CANADA, Ottawa, ON, Canada, 3University of Florida College of Medicine - Jacksonville, Jacksonville, FL

    Background/Purpose: DUET is a study supported by the Group for Assessment for Psoriasis and Psoriatic Arthritis (GRAPPA) that aims to develop a novel sonographic scoring…
  • Abstract Number: 0317 • ACR Convergence 2020

    Axial Involvement in Psoriatic Arthritis in a Comprehensive Rapid Diagnosis Program (Reuma-check PsA). Analysis of Its Characteristics

    Rodrigo Garcia Salinas1, Santiago Ruta2, Jessica Torres Chichande1, Einer Sanchez Prado1, Facundo Salvatori1 and Sebastian Magri1, 1Hospital Italiano La Plata, La Plata, Argentina, 2Hospital Italiano La Plata, Buenos Aires, Argentina

    Background/Purpose: To date, there is no consensus that allows an appropriate definition of axial involvement in PsA, that ranges between 25 to 70%. To estimate…
  • Abstract Number: 0805 • ACR Convergence 2020

    The PROPER Study: Results of the First Interim Analysis of a Pan-EU Real-World Study of SB5 Biosimilar Following Transition from Reference Adalimumab in Patients with Rheumatoid Arthritis, Axial Spondyloarthritis or Psoriatic Arthritis

    Ulf Müller-Ladner1, Karl Gaffney2, Deepak Jadon3, Ulrich Freudensprung4 and Janet Addison5, 1Department of Rheumatology, Immunology, Osteology and Physical Medicine, Justus Liebig University Gießen, Campus Kerckhoff, Bad Nauheim, Germany, Bad Nauheim, Germany, 2Norfolk and Norwich University Hospital NHS Foundation Trust, Norfolk, United Kingdom, 3Cambridge University Hospitals NHSFT, Cambridge, United Kingdom, 4Biogen International GmbH, Baar, Switzerland, 5Biogen Idec, Maidenhead, United Kingdom

    Background/Purpose: SB5, an adalimumab biosimilar received EU marketing authorisation in August 2017, based on the totality of evidence from pre-clinical and clinical Phase I and…
  • Abstract Number: 1031 • ACR Convergence 2020

    Real World Treatment Patterns Among Patients with Psoriatic Arthritis Treated with Ixekizumab

    Mwangi Murage1, Nicole Princic2, Julie Park2, William Malatestinic1, Baojin Zhu1, Bilal Atiya1, Scott Kern1, Keri Stenger1, Aubrey Sprabery1 and Alexis Ogdie3, 1Eli Lilly and Company, Indianapolis, IN, 2IBM Watson Health, Cambridge, MA, 3University of Pennsylvania, Philadelphia, PA

    Background/Purpose: Psoriatic arthritis (PsA) is a systemic condition estimated to affect 0.05%-0.25% of the United States (US)1 population. With approval of ixekizumab (a selectively binding…
  • Abstract Number: 1333 • ACR Convergence 2020

    Ankylosing Spondylitis Patients at Risk of Developing Aortic Valve Regurgitation, Need for Mandatory Echocardiography?

    Milad Baniaamam1, Sjoerd C. Heslinga2, Laura Boekel1, M. Louis Handoko3, Thelma C. Konings3, Otto Kamp3, Vokko P. van Halm4, J. Christiaan van Denderen1, Irene van der Horst-Bruinsma2 and Mike Nurmohamed5, 1Reade, Amsterdam, Netherlands, 2Department of Rheumatology, Amsterdam UMC, location VU University Medical Centre, Amsterdam, Netherlands, 3Department of Cardiology, Amsterdam UMC, location VU University Medical Centre, Amsterdam, Netherlands, 4Department of Cardiology, Amsterdam UMC, location VU University Medical Centre, Amsterdam, 5Amsterdam Rheumatology and immunology Center, location Reade and Amsterdam UMC, VU medical center, Amsterdam, Netherlands

    Background/Purpose: The overall mortality rate in ankylosing spondylitis (AS) patients is increased by 60–90% compared with the general population. This higher mortality rate is predominately…
  • Abstract Number: 1518 • ACR Convergence 2020

    The Role for Neutrophils in the Early Phases of Enthesitis in Spondyloarthritis

    Zheni Stavre1, Charles Bridgewood2, Qiao Zhou2, Yukiko Maeda3, Jozsef Karman4, Dennis McGonagle5 and Ellen Gravallese6, 1University of Massachusetts Medical School-Rheumatology Division, Worcester, MA, 2University of Leeds, Leeds, United Kingdom, 3University of Massachusetts Medical School, worcester, MA, 4Abbvie Inc., Worcester, MA, 5The University of Leeds, Leeds Institute for Rheumatic and Musculoskeletal Medicine, NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals Trust, Leeds, UK, Leeds, United Kingdom, 6Brigham and Women's Hospital, Boston, MA

    Background/Purpose: Neutrophils are present in the early phases of spondyloarthritis (SpA)-associated uveitis, skin and intestinal disease, but their role in enthesitis remains unknown. We investigated…
  • Abstract Number: 1865 • ACR Convergence 2020

    Identification of Parameters Associated with a Diagnostic Delay in Axial Spondyloarthritis:Results from the European Map of Axial Spondyloarthritis (EMAS)

    Marco Garrido-Cumbrera1, Victoria Navarro-Compán2, Christine Bundy3, Raj Mahapatra4, Souzi Makri5, José Correa-Fernández6, Laura Christen7, Carlos-Jesus Delgado-Domínguez8 and Denis Poddubnyy9, 1Health & Territory Research (HTR), Universidad de Sevilla / Spanish Federation of Spondyloarthritis Associations, Sevilla, Spain, 2Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, 3Cardiff University, Cardiff, United Kingdom, 4Axial Spondyloarthritis International Federation, London, United Kingdom, 5Cyprus League Against Rheumatism, Nicosia, Cyprus, 6Health & Territory Research (HTR), Universidad de Sevilla, Sevilla, Spain, 7Novartis Pharma AG, Basel, Switzerland, 8Health & Territory Research, Seville, Spain, 9Charité – Universitätsmedizin Berlin, Berlin, Germany

    Background/Purpose: Early diagnosis of Axial Spondyloarthritis (axSpA) is crucial for timely access to specialist care and effective treatment. The aim is to assess the current…
  • Abstract Number: 1895 • ACR Convergence 2020

    Radiographic Progression in Patients with Axial Spondyloarthritis Under Treatment with TNF Inhibitors. Data from REGISPONSERBIO (Spanish Register of Biological Therapy in Spondyloarthritides)

    Maria Llop1, Mireia Moreno2, Jordi Gratacós3, Victoria Navarro-Compán4, Eugenio De Miguel5, Pilar Font6, Teresa Clavaguera7, Luis Francisco Linares8, Beatriz Joven9 and Xavier Juanola10, 1Hospital Universitari Parc Taulí I3PT, Sabadell, Catalonia, Spain, 2Hospital Universitari Parc Taulí I3PT, Sabadell, Spain, 3University Hospital Parc Tauli Sabadell, Barcelona, Spain, 4Hospital Universitario La Paz IdiPaz, Madrid, Pais Vasco, Spain, 5Rheumatology Department, Hospital Universitario La Paz, Madrid, Spain, 6Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Córdoba, Spain, 7Hospital Universitari Trueta, Girona, Spain, 8Hospital de la Arrixaca, Murcia, 9Hospital Universitario 12 de Octubre, Madrid, Spain, 10Rheumatology Service, University Hospital Bellvitge, IDIBELL, Barcelona, Spain, Barcelona, Spain

    Background/Purpose: Clinical efficacy of TNF inhibitors (TNFi) in axial spondyloarthritis (axSpA) has been widely probed in randomized control trials. In clinical practice, some studies suggested…
  • Abstract Number: 2022 • ACR Convergence 2020

    Effects of Anti-TNF-therapy on Osteoblastic Activity in Ankylosing Spondylitis – Results from a Prospective Study Using PET-MRI of SIJ and Spine

    Xenofon Baraliakos1, Styliani Tsiami2, Christoph Rischpler3, Nils-Martin Bruckmann4, Wolfgang Fendler3, Julian Kirchner5, Ken Herrmann3, Lino Morris Sawicki5 and Juergen Braun6, 1Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, 2Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, 3Department of Nuclear Medicine, University Essen-Duisburg, Essen, Germany, 4Department of Radiology, University Duesseldorf, Düsseldorf, Germany, 5Department of Radiology, University Duesseldorf, Duesseldorf, Germany, 6Rheumazentrum Ruhrgebiet Herne, and Ruhr-University Bochum, 44649 Herne, Germany

    Background/Purpose: The clinical efficacy of TNFi in patients with axSpA is well established but its effect on new bone formation is still unclear. Positron emission…
  • Abstract Number: 0341 • ACR Convergence 2020

    Metabolomics Profiling of Human Serum for Discovering Biomarkers to Diagnose Psoriatic Arthritis and Ankylosing Spondylitis with High Specificity

    Wei Han1, Xiaohang Wang1, Liang Li1, Stephanie Wichuk2, Edna Hutchings3, Rana Dadashova3, Joel Paschke3 and Walter Maksymowych2, 1Department of Chemistry, University of Alberta, Edmonton, AB, Canada, 2University of Alberta, Edmonton, AB, Canada, 3CARE Arthritis, Edmonton, AB, Canada

    Background/Purpose: In this work, we applied a high-performance chemical isotope labeling (CIL) LC-MS platform to search for biomarker candidates of PsA and AS in human…
  • « Previous Page
  • 1
  • …
  • 35
  • 36
  • 37
  • 38
  • 39
  • …
  • 41
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology